ValiRx achieves success in latest VAL201 trial

ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients.

The AIM-traded life science company, with a focus on cancer diagnostics and therapeutics for personalised medicine, said that a further cohort of subjects had completed the core part of their clinical trial dosing sequence with no significant adverse effects reported.

It followed ValiRx's quarterly update on 9 February, in which it reported that no adverse effects had been observed in the first part of the trial.

In light of Tuesday's news, the trial's Cohort Review Committee recommended that the final dose escalation be approved.

"The trial itself continues according to its approved design, and its schedule is on time," the company's board confirmed in a statement.

"Further updates and information will be provided during the dose expansion phase, during which the specific tumour modulating effects that were shown preclinically and have been hinted at during the in-human stage, are being specifically investigated," it added.

VAL201 was a compound being developed and tested for the treatment of hormone resistant prostate cancer, with a future possibility of it being used to treat endometrioisis following good pre-clinical results.